期刊文献+

大肠杆菌脂蛋白与CTB-pres2抗原基因的融合及表达 被引量:6

Gene Fusion and Expression of Lipoprotein with Cholera Toxin B Subunit and HBV Pres2 Epitope
原文传递
导出
摘要 首次采用基因融合方式,在乱毒素B亚基-乙型肝炎病毒Pres2抗原融合基因(ctxB-Pres2)的5’端了引入编码大肠杆菌脂蛋白信号肽及N端九个氨基酸的核苷酸序列,分别置于ctb及lpp/lac启动子下在大肠杆菌中获得分泌性表达.表达的融合蛋白均定位于膜上,并且可以和GM1、抗-CTB抗体及抗HBVPreS2单克隆抗体结合,说明该融合蛋白保留了CTB的基本高级结构及CTB、PreS2抗原的抗原性.3H-棕榈酸标记实验证实该融合蛋白发生脂肪化,为免疫原性研究奠定了基础.此外,还研究了不同信号肽和宿主菌对该蛋白表达的影响. Lipoprotein(lpp)of the outer membrane of E. coli is a major protein of the cell wall.N-terminal amino acids of lipoprotein and its artifical analogues were promising adjuvant in construction of peptide vaccine for their activity activating B-lymphocyte,macrophage and CTL. Nucleotides encoding signal peptide and N-terminal nine amino acids(LPP9)of lipoprotein were genetically fused to 5'end of ctxB-Pres2 gene by means of PCR. The fusion protein was well expressed with relatively low yield (about 0.1-0. 2mg/l),and anchored in cell membrane. The fusion protein obtained in this way was more convenient and economical than chemical conjugation.The chimera was modified correctly and retained the biological activity of both CTB and Pres2 as confirmed by 3H-palmitic acid labelling test and GM I Enzyme Linked lmmunosorbent Assay respectively. It was also demonstrated that the signal peptide of lipoprotein was important to the correct modification of the chimera,and ctxB promoter was more efficient than that of lpp on the expression of chimera. Studies on the immunogenicity of the chimera are now in progress.
出处 《生物化学杂志》 CSCD 1997年第3期276-281,共6页
关键词 脂蛋白 霍乱毒素B亚基 乙型肝炎病毒 基因融合 Lipoprotein, HBV, Cholera toxin B subuint, Gene fusion
  • 相关文献

参考文献3

  • 1石成华,Vaccine,1995年,13卷,933页
  • 2石成华,生物化学杂志,1994年,10卷,533页
  • 3朱平,抗体实验技术,1994年,282页

同被引文献69

  • 1曹素芳,黄青云,张煜坤,温纳相,陈红英.禽大肠杆菌外膜蛋白基因C(ompC)的序列分析[J].中国兽医学报,2004,24(4):332-334. 被引量:4
  • 2姜永萍,于康震,邓国华,田国斌,乔传玲,陈化兰.表达H5亚型禽流感病毒HA基因的DNA疫苗免疫保护效力研究[J].中国农业科学,2004,37(7):1071-1075. 被引量:11
  • 3王克夷.肽链的翻译后加工2.新生肽链穿越粗面内质网系膜[J].生命的化学,1995,15(2):1-4. 被引量:3
  • 4李军,李伯良.蛋白A信号肽引导的E.coli外泌高表达异源蛋白[J].生物化学与生物物理学报,1995,27(6):616-623. 被引量:4
  • 5Wuorimaa T, Dagan R, Eskola J, et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers [ J ]. Pediatr Infect Dis J, 21301, 20 ( 3 ) : 272-277.
  • 6谢贵林.流感嗜血杆菌疫苗--b型流感嗜血杆菌结合疫苗[M]//赵铠.章以浩,李河民.医学生物制品学.2版.北京:人民卫生出版社,2007:540-560.
  • 7Snape MD, Perrett KP, Ford KJ. et al. lmmunogenieity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial [ J]. JAMA, 2008, 299 ( 2 ) : 217-219.
  • 8Centers for Disease Control and Prevention. Recommended childhood immunization schedule--United States, 2001 [ J].JAMA, 2001. 285(7) : 875-876.
  • 9Kim NH, Lee J, Lee SJ, et al. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine( diphtheria CRM( 197 )protein conjugate; Prcvenar) in Korean infants: differences that are found in Asian children [J ]. Vaccine, 2007, 25 (45) : 7858-7865.
  • 10Silva R, Selman HS, Guillen W, et al. Nucleotide sequence coding for an outer membrane protein from Neisseria meningitids and use said protein in vaccine preparations:US, 5286484 [ P]. 1994-02-15.

引证文献6

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部